Number of patients (%) | ||
---|---|---|
Study cohort on TMA (n=11152) | Biochemical relapse among categories (n=1824) | |
Follow-up (months) | ||
Mean | 53.4 | – |
Median | 36.8 | – |
Age (years) | ||
<50 | 318 | 49 |
50–60 | 2.768 | 460 |
60–70 | 6.548 | 1.081 |
>70 | 1.439 | 232 |
Pretreatment PSA (ng/ml) | ||
<4 | 1.407 | 142 |
4–10 | 6.735 | 827 |
10–20 | 2.159 | 521 |
>20 | 720 | 309 |
Tumour stage | ||
pT2 | 7.370 | 570 |
pT3a | 2.409 | 587 |
pT3b | 1.262 | 618 |
pT4 | 63 | 49 |
Gleason grade | ||
<3+3 | 2.859 | 193 |
3+4 | 1.565 | 573 |
4+3 | 6.183 | 849 |
>4+4 | 482 | 208 |
Lymph node metastasis | ||
pN0 | 6.117 | 1.126 |
pN+ | 561 | 291 |
Surgical margin | ||
Negative | 8.984 | 1.146 |
Positive | 1.970 | 642 |
Numbers do not always add up to 11 152 in the different categories because of cases with missing data.